NantKwest Signs Worldwide License Agreement with ProMab
![NantKwest Signs Worldwide License Agreement with ProMab](https://files.promab.com/production/Slide1_8b47c799a0.png)
Initially Launching a Novel, High-Affinity BCMA CAR Targeting NK Cell Development Candidate For Multiple Myeloma, With An Option For Up To Five Additional CAR Targeting Sequences.
ProMab and NantKwest recently launched a collaboration to develop BCMA CAR-NK cell development.
Read more >